Aibotics, INC. (AIBT) — SEC Filings

Q: What are the key financial highlights for Aibotics, INC.?

Key financial highlights for Aibotics, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Aibotics, INC.?

Key executives at Aibotics, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Aibotics, INC. stock?

Risk factors for Aibotics, INC. (AIBT) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Aibotics, INC.?

Forward-looking statements and predictions from Aibotics, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Aibotics, INC.. Recent 10-Q filing on Nov 19, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Aibotics, INC. on SEC EDGAR

Overview

Aibotics, INC. (AIBT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 19, 2025: AIBOTICS, INC. (AIBT) reported a net loss of $1,607,467 for the nine months ended September 30, 2025, an increase from a net loss of $1,356,761 in the same period of 2024. The company generated minimal revenue of $2,183 for the nine months ended September 30, 2025, compared to zero revenue in the pr

Sentiment Summary

Across 11 filings, the sentiment breakdown is: 1 bearish, 10 neutral. The dominant filing sentiment for Aibotics, INC. is neutral.

Filing Type Overview

Aibotics, INC. (AIBT) has filed 6 10-Q, 2 10-K, 3 8-K with the SEC between Mar 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (11)

AIBOTICS' Losses Widen Amidst Minimal Revenue, Going Concern Doubt — 10-Q · Nov 19, 2025 Risk: high
AIBOTICS, INC. (AIBT) reported a net loss of $1,607,467 for the nine months ended September 30, 2025, an increase from a net loss of $1,356,761 in the same peri
AIBOTICS, INC. Files Q2 2025 10-Q Report — 10-Q · Aug 19, 2025 Risk: low
AIBOTICS, INC. filed its quarterly report for the period ending June 30, 2025. The company, formerly known as Mycotopia Therapies, Inc. and 20/20 Global, Inc.,
AIBOTICS, INC. Files Q1 2025 10-Q — 10-Q · May 20, 2025 Risk: low
AIBOTICS, INC. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Mycotopia Therapies, Inc. and 20/20 Global, Inc., is in the m
AIBotics, Inc. Files 2024 10-K — 10-K · Apr 11, 2025 Risk: medium
AIBotics, Inc. filed its 2024 10-K on April 11, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Mycotopia Therapies,
Aibotics, Inc. Files 8-K for Material Agreement — 8-K · Mar 24, 2025 Risk: medium
Aibotics, Inc. filed an 8-K on March 24, 2025, reporting on events as of January 25, 2025. The filing indicates an entry into a material definitive agreement an
Mycotopia Therapies Files Q3 2024 10-Q Report — 10-Q · Nov 14, 2024 Risk: medium
Mycotopia Therapies, Inc. filed its quarterly report on Form 10-Q for the period ending September 30, 2024. The company, previously known as 20/20 Global, Inc.,
Mycotopia Therapies Files 8-K with Material Agreements — 8-K · Aug 21, 2024 Risk: medium
Mycotopia Therapies, Inc. filed an 8-K on July 29, 2024, reporting a material definitive agreement and amendments to its articles of incorporation. The company,
Mycotopia Therapies Files Q2 2024 10-Q — 10-Q · Aug 19, 2024 Risk: medium
Mycotopia Therapies, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as 20/20 Global, Inc., is incorporated in Nevada and o
Mycotopia Therapies, Inc. Files Form 10-Q for Period Ending March 31, 2024 — 10-Q · May 15, 2024 Risk: low
Mycotopia Therapies, Inc. (AIBT) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Mycotopia Therapies, Inc. filed a Form 10-Q for the quarterly per
Mycotopia Therapies, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Apr 23, 2024 Risk: medium
Mycotopia Therapies, Inc. (AIBT) filed a Annual Report (10-K) with the SEC on April 23, 2024. Mycotopia Therapies, Inc. (formerly 20/20 Global, Inc.) filed its
Mycotopia Therapies Changes Certifying Accountant — 8-K · Mar 28, 2024 Risk: low
Mycotopia Therapies, Inc. filed an 8-K on March 28, 2024, reporting a change in its certifying accountant. The company previously engaged with a different accou

Risk Profile

Risk Assessment: Of AIBT's 11 recent filings, 1 were flagged as high-risk, 6 as medium-risk, and 4 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Aibotics, INC.'s most recent 10-Q filing (Nov 19, 2025):

Revenue: $2,183
Net Income: -$1,607,467
EPS: -$0.02
Debt-to-Equity: N/A
Cash Position: $230,470
Operating Margin: N/A
Total Assets: $1,016,943
Total Debt: $4,902,572

Industry Context

AIBOTICS, INC. operates in a sector that often requires significant R&D investment and faces long development cycles. The competitive landscape can be intense, with established players and emerging startups vying for market share and funding. Industry trends often involve rapid technological advancements and evolving regulatory frameworks, demanding continuous innovation and adaptation.

Top Tags

10-Q (5) · company-information (3) · financials (3) · quarterly-report (2) · 10-K (2) · material-agreement (2) · filing (2) · Mycotopia Therapies (2) · SEC Filing (2) · Financials (2)

Key Numbers

Net Loss: $1.61M — Increased from $1.36M in 2024 for the nine months ended September 30.
Revenue: $2.18K — Minimal revenue for the nine months ended September 30, 2025, up from $0 in 2024.
Working Capital Deficit: $4.66M — Significant deficit as of September 30, 2025, indicating severe liquidity issues.
Cash: $230.47K — Cash balance as of September 30, 2025, a slight increase from $185K at year-end 2024.
Operating Expenses: $1.37M — Increased from $1.14M in 2024 for the nine months ended September 30.
Shares Outstanding: 440.6M — As of November 19, 2025, indicating significant dilution.
Net Loss Per Share: $0.02 — For the nine months ended September 30, 2025, compared to $0.11 in 2024, due to increased share count.
Amortization Expense: $496.35K — For the nine months ended September 30, 2025, contributing to intangible asset reduction.
Reporting Period End Date: 20250630 — Indicates the end of the fiscal quarter for this filing.
Filing Date: 20250819 — The date the 10-Q was officially submitted to the SEC.
Fiscal Year End: 2024-12-31 — Reporting period covered by the 10-K
SEC File Number: 000-56022 — Identifies the specific filing for Aibotics, Inc.
IRS Employer ID No.: 87-0645794 — Tax identification number for Aibotics, Inc.
Name Change Date: 20190102 — Indicates when the company officially changed its name from 20/20 Global, Inc.
Period End Date: 20240630 — The end of the reporting period for this 10-Q filing.

Frequently Asked Questions

What are the latest SEC filings for Aibotics, INC. (AIBT)?

Aibotics, INC. has 11 recent SEC filings from Mar 2024 to Nov 2025, including 6 10-Q, 3 8-K, 2 10-K. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of AIBT filings?

Across 11 filings, the sentiment breakdown is: 1 bearish, 10 neutral. The dominant sentiment is neutral.

Where can I find Aibotics, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Aibotics, INC. (AIBT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Aibotics, INC.?

Key financial highlights from Aibotics, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for AIBT?

The investment thesis for AIBT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Aibotics, INC.?

Executive information for Aibotics, INC. is extracted from SEC filings as they are enriched with AI analysis.

What are the main risk factors for Aibotics, INC. stock?

Of AIBT's 11 assessed filings, 1 were flagged high-risk, 6 medium-risk, and 4 low-risk.

What are recent predictions and forward guidance from Aibotics, INC.?

Forward guidance and predictions for Aibotics, INC. are extracted from SEC filings as they are enriched.